AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18217177 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 208
Study 18217177 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 208
Study 11115412 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily for 4 weeks)
Number of subjects: 12
Study 9117878 — intervention group
Group type: EXPERIMENTAL
Intervention: RV16 treatment (0.5-2.9 x 10(4) TCID50)
Number of subjects: 27
Study 9117878 — intervention group
Group type: EXPERIMENTAL
Intervention: RV16 treatment
Number of subjects: 27
Study 7709688 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-Analogues
Number of subjects: 0
Study 2954222 — intervention group
Group type: EXPERIMENTAL
Intervention: Balans chair
Number of subjects: 20
Study 2954222 — intervention group
Group type: COMPARATOR
Intervention: Conventional office chair
Number of subjects: 20
Study 31846974 — intervention group
Group type: EXPERIMENTAL
Intervention: High c-Met expression in primary HCC cases
Number of subjects: 319
Study 31846974 — intervention group
Group type: COMPARATOR
Intervention: Low c-Met expression in primary HCC cases
Number of subjects: 319
Study 31846974 — intervention group
Group type: EXPERIMENTAL
Intervention: High c-Met expression in 40 cases
Number of subjects: 319
Study 30376095 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV followed by IPV at 14 weeks
Number of subjects: 260
Study 30376095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IPV at 8 weeks followed by 2 doses of bOPV
Number of subjects: 260
Study 30376095 — intervention group
Group type: EXPERIMENTAL
Intervention: Second IPV dose at 16 weeks
Number of subjects: 260
Study 30376095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential IPV-bOPV
Number of subjects: 260
Study 30376095 — intervention group
Group type: COMPARATOR
Intervention: Mixed bOPV-IPV schedule
Number of subjects: 260
Study 27935537 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PD solution
Number of subjects: 161
Study 27935537 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal ultrafiltration (UF)
Number of subjects: 161
Study 27935537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate glucose exposure
Number of subjects: 161
Study 25610918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing 2% green tea
Number of subjects: 110
Study 25610918 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 110
Study 22197120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT; 3-minute intervals at 40% and 80% VO(2peak))
Number of subjects: 45
Study 22197120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 45
Study 22197120 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT; sustained 60% VO for 30 min/day, 3 days/week for 12 weeks)
Number of subjects: 45
Study 22197120 — intervention group
Group type: COMPARATOR
Intervention: General Healthcare (GHC)
Number of subjects: 45
Study 21262565 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (up to 15 mg/day)
Number of subjects: 31
Study 21262565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18234392 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UVB
Number of subjects: 20
Study 18234392 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1
Number of subjects: 20
Study 18234392 — intervention group
Group type: COMPARATOR
Intervention: Control (opaque tape)
Number of subjects: 20
Study 18234392 — intervention group
Group type: COMPARATOR
Intervention: Control (sunscreen)
Number of subjects: 20
Study 18234392 — intervention group
Group type: COMPARATOR
Intervention: Control (unprotected)
Number of subjects: 20
Study 17165277 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg/d
Number of subjects: 40
Study 17165277 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg/d
Number of subjects: 40
Study 17165277 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast + Desloratadine
Number of subjects: 40
Study 17165277 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine, 5 mg/d
Number of subjects: 40
Study 17165277 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 5 mg/d
Number of subjects: 40
Study 17165277 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast + Levocetirizine
Number of subjects: 40
Study 17165277 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast + Antihistamine (Desloratadine or Levocetirizine)
Number of subjects: 40
Study 17165277 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast + Antihistamine
Number of subjects: 40
Study 14556770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic reflexology technique
Number of subjects: 55
Study 14556770 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing reflexology technique
Number of subjects: 55
Study 14556770 — intervention group
Group type: COMPARATOR
Intervention: Period of rest
Number of subjects: 55
Study 10892625 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) therapy, 6 hours/day for 6 weeks, targeting supraspinatus and posterior deltoid muscles.
Number of subjects: 0
Study 8896952 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sodium dodecyl sulfate (SDS)
Number of subjects: 58
Study 8896952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrochloric acid (HCl)
Number of subjects: 58
Study 8896952 — intervention group
Group type: EXPERIMENTAL
Intervention: undiluted cocotrimethyl ammonium chloride (coco TAC)
Number of subjects: 58
Study 1356519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine (800 mg)
Number of subjects: 20
Study 30945430 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing 5% panthenol, madecassoside, and copper-zinc-manganese (experimental cream)
Number of subjects: 20
Study 30945430 — intervention group
Group type: COMPARATOR
Intervention: 0.02% Triamcinolone acetonide cream (TA cream)
Number of subjects: 20
Study 29241431 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Navigator Program (PNP)
Number of subjects: 110
Study 29241431 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 110
Study 26859559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) - 1 sachet/day for 14 days
Number of subjects: 2213
Study 26859559 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) - 2 sachets/day for 14 days
Number of subjects: 2213
Study 26859559 — intervention group
Group type: COMPARATOR
Intervention: Control - no supplement
Number of subjects: 2213
Study 26859559 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF vs Control
Number of subjects: 2213
Study 26859559 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP vs Control
Number of subjects: 2213
Study 26859559 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF vs MNP
Number of subjects: 2213
Study 26859559 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF
Number of subjects: 2213
Study 26859559 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP
Number of subjects: 2213
Study 26859559 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2213
Study 24863949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin-metformin combination regimen
Number of subjects: 2000
Study 24863949 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care metformin monotherapy
Number of subjects: 2000
Study 22175269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription review sent to physician
Number of subjects: 150
Study 22175269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription review sent to physician and current comprehensive medication record sent to the patient
Number of subjects: 150
Study 22175269 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 18783424 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard U‐shaped bar (Dolder bar) - Group A
Number of subjects: 0
Study 18783424 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment bar - Group B
Number of subjects: 0
Study 18783424 — intervention group
Group type: COMPARATOR
Intervention: Both bar designs
Number of subjects: 0
Study 18783424 — intervention group
Group type: COMPARATOR
Intervention: Attachment bar
Number of subjects: 0
Study 18418965 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM) group treated with aspirin, Clopidogrel, statins
Number of subjects: 70
Study 18418965 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine (TCM) group treated with Dahuang Zhechong Pill, Tianma Duzhong Capsule, and self‐formulated decoctions
Number of subjects: 70
Study 18418965 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) group treated with both TCM and WM
Number of subjects: 70
Study 16178131 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) rinse (Crest Pro‐Health Rinse)
Number of subjects: 78
Study 16178131 — intervention group
Group type: COMPARATOR
Intervention: Essential oils (EO) rinse (Cool Mint Listerine)
Number of subjects: 78
Study 14606705 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg Talpha1 (low dose group; n = 8)
Number of subjects: 16
Study 14606705 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg Talpha1 (high dose group; n = 8)
Number of subjects: 16
Study 14606705 — intervention group
Group type: EXPERIMENTAL
Intervention: Talpha1 therapy
Number of subjects: 16
Study 10772202 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal hemolytic illness
Number of subjects: 45
Study 10772202 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin
Number of subjects: 45
Study 10772202 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin/albumin ratio
Number of subjects: 45
Study 8894384 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support system for oral hypoglycaemic therapy
Number of subjects: 218
Study 8894384 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal procedures)
Number of subjects: 218
Study 1893092 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended tones (specific pitches and ear)
Number of subjects: 0
Study 1893092 — intervention group
Group type: COMPARATOR
Intervention: Ignored tones
Number of subjects: 0
Study 1893092 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature-conjunction operations
Number of subjects: 0
Study 6466184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine hydrochloride eyedrops
Number of subjects: 10
Study 6466184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 30896452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy
Number of subjects: 79
Study 30896452 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 79
Study 30021449 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (IG)
Number of subjects: 4685
Study 30021449 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (DG)
Number of subjects: 4685
Study 30021449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of early treatment
Number of subjects: 4685
Study 27287084 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG/EE extended regimen (84 days of LNG 150 μg/EE 30 μg with 7 days of EE 10 μg)
Number of subjects: 829
Study 27287084 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG/EE 21/7 (21 days of LNG 100 μg/EE 20 μg with 7 days of placebo)
Number of subjects: 829
Study 25175787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based home exercise training program
Number of subjects: 26
Study 25175787 — intervention group
Group type: COMPARATOR
Intervention: Control group (free walk)
Number of subjects: 26
Study 21954131 — intervention group
Group type: EXPERIMENTAL
Intervention: ESCAPE‐knee pain program
Number of subjects: 418
Study 21954131 — intervention group
Group type: COMPARATOR
Intervention: Usual care (pragmatic control)
Number of subjects: 418
Study 19228250 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mentored (PM) fitness program
Number of subjects: 131
Study 19228250 — intervention group
Group type: COMPARATOR
Intervention: Student-mentored (SM) fitness program
Number of subjects: 131
Study 18341239 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern clinical testing protocol for controlled clinical trials
Number of subjects: 0
Study 18341239 — intervention group
Group type: EXPERIMENTAL
Intervention: Categories of assessment for esthetic evaluation, functional assessment, biological responses to restorative materials
Number of subjects: 0
Study 18341239 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of results
Number of subjects: 0
Study 14973528 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5-2.5 mg daily for 4 months
Number of subjects: 84
Study 14973528 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 84
Study 11245843 — intervention group
Group type: EXPERIMENTAL
Intervention: Target merging (merging pairs of items, e.g., connecting item locations with a line segment or drawing the convex hull)
Number of subjects: 0
Study 11245843 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9840855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance with 20 mL 0.5% bupivacaine
Number of subjects: 60
Study 9840855 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator (NS) guidance with 20 mL 0.5% bupivacaine
Number of subjects: 60
Study 9840855 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator (NS) guidance with 30 mL 0.5% bupivacaine
Number of subjects: 60
Study 9840855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 60
Study 9840855 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator (NS) guidance
Number of subjects: 60
Study 8089391 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PAL)
Number of subjects: 1713
Study 8089391 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioners with fitting skills
Number of subjects: 1713
Study 8089391 — intervention group
Group type: COMPARATOR
Intervention: Practitioners without fitting skills
Number of subjects: 1713
Study 2510959 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase therapy (two weeks administration)
Number of subjects: 57
Study 2510959 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase therapy (consecutive administration)
Number of subjects: 57
Study 2510959 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet drugs (control)
Number of subjects: 57
Study 52896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyloestrenol
Number of subjects: 0
Study 52896 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenolone acetate
Number of subjects: 0
Study 52896 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethandrolone
Number of subjects: 0
Study 52896 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylandrostenediol
Number of subjects: 0
Study 52896 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetholone
Number of subjects: 0
Study 52896 — intervention group
Group type: EXPERIMENTAL
Intervention: Methandienone
Number of subjects: 0
Study 52896 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol
Number of subjects: 0
Study 30753776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention community (educational intervention to prevent childhood obesity)
Number of subjects: 214
Study 30753776 — intervention group
Group type: COMPARATOR
Intervention: Control community (no intervention)
Number of subjects: 214
Study 28822956 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention (mobile-oriented site)
Number of subjects: 17
Study 26353947 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 540
Study 26353947 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-metformin antidiabetic medications
Number of subjects: 540
Study 26353947 — intervention group
Group type: COMPARATOR
Intervention: No antidiabetic medication
Number of subjects: 540
Study 22893251 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 88
Study 20730613 — intervention group
Group type: EXPERIMENTAL
Intervention: CT fluoroscopy-guided NAB (Group I, n = 72)
Number of subjects: 142
Study 20730613 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT-guided NAB (Group II, n = 70)
Number of subjects: 142
Study 18946177 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with gastroparesis
Number of subjects: 55
Study 18946177 — intervention group
Group type: COMPARATOR
Intervention: Patients without gastroparesis or healthy controls
Number of subjects: 55
Study 18946177 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with autonomic neuropathy
Number of subjects: 55
Study 18946177 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus without autonomic neuropathy
Number of subjects: 55
Study 16996462 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer-based method (CD-ROM)
Number of subjects: 39
Study 16996462 — intervention group
Group type: COMPARATOR
Intervention: Conventional paper-based method
Number of subjects: 39
Study 12956916 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures taken within two minutes after tonsillectomy (Group 1)
Number of subjects: 64
Study 12956916 — intervention group
Group type: COMPARATOR
Intervention: Blood cultures taken 15 minutes after tonsillectomy (Group 2)
Number of subjects: 64
Study 10811692 — intervention group
Group type: COMPARATOR
Intervention: Dysport 1500 Units
Number of subjects: 74
Study 10811692 — intervention group
Group type: COMPARATOR
Intervention: Dysport (500, 1000, or 1500 Units)
Number of subjects: 74
Study 10811692 — intervention group
Group type: COMPARATOR
Intervention: Dysport (1000 or 1500 Units)
Number of subjects: 74
Study 10811692 — intervention group
Group type: COMPARATOR
Intervention: Dysport 500 Units
Number of subjects: 74
Study 10811692 — intervention group
Group type: COMPARATOR
Intervention: Dysport 1000 Units
Number of subjects: 74
Study 10811692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 10811692 — intervention group
Group type: COMPARATOR
Intervention: Dysport
Number of subjects: 74
Study 8880292 — intervention group
Group type: EXPERIMENTAL
Intervention: Holy basil leaves
Number of subjects: 0
Study 8880292 — intervention group
Group type: COMPARATOR
Intervention: Placebo leaves
Number of subjects: 0
Study 1995769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (ICT, n = 44)
Number of subjects: 97
Study 1995769 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (RT, n = 53)
Number of subjects: 97
Study 6402199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 15 mg
Number of subjects: 18
Study 6402199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29325486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive client-centred occupational therapy (ICC-OT) - maximum 22 sessions
Number of subjects: 119
Study 29325486 — intervention group
Group type: COMPARATOR
Intervention: Usual practice - maximum 3 sessions of occupational therapy
Number of subjects: 119
Study 31159805 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured information delivery, personalised written physical activity prescription (number of steps per day), pedometer, and pedometer logbook.
Number of subjects: 140
Study 31159805 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured information delivery, personalised written physical activity prescription, pedometer, and pedometer logbook.
Number of subjects: 140
Study 31159805 — intervention group
Group type: COMPARATOR
Intervention: Verbal advice of physical exercise (Control group).
Number of subjects: 140
Study 28155057 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentectomy
Number of subjects: 49
Study 28155057 — intervention group
Group type: COMPARATOR
Intervention: No omentectomy (Control)
Number of subjects: 49
Study 26156108 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program for protocol-directed weaning
Number of subjects: 884
Study 23439346 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 39
Study 23439346 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity stretching
Number of subjects: 39
Study 23439346 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity or high-intensity stretching
Number of subjects: 39
Study 21971664 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (GLN) 15g/day
Number of subjects: 20
Study 21971664 — intervention group
Group type: COMPARATOR
Intervention: Milk protein 15g/day (Control)
Number of subjects: 20
Study 18278978 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR 150 mg/day
Number of subjects: 1524
Study 18278978 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR 300 mg/day
Number of subjects: 1524
Study 17099376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefuroxime 750 mg just before the procedure followed by two further doses every 8 h (Group A)
Number of subjects: 96
Study 17099376 — intervention group
Group type: COMPARATOR
Intervention: Single application of povidone-iodine (Betadine) antiseptic spray (Group B)
Number of subjects: 96
Study 17099376 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cefuroxime and Betadine spray (Group C)
Number of subjects: 96
Study 12958051 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation
Number of subjects: 130
Study 12958051 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy plus O2
Number of subjects: 130
Study 11189691 — intervention group
Group type: EXPERIMENTAL
Intervention: Death review process in the PLCO Cancer Screening Trial
Number of subjects: 0
Study 9308557 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine-lidocaine patch (anesthetic patch)
Number of subjects: 60
Study 9308557 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 60
Study 8346498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.08‐2.0 mg)
Number of subjects: 20
Study 8346498 — intervention group
Group type: COMPARATOR
Intervention: Nicotine (2.0 mg given eight times daily for nine days)
Number of subjects: 20
Study 8346498 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge after acute doses of nicotine
Number of subjects: 20